Overview

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2026-04-15

Target enrollment:

Participant gender:

Summary

Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 negative rate as primary end point in patients with early Relapsed or Refractory Multiple Myeloma. Therapeutic study, phase II, prospective, multicenter, open-label. The patients will be treated until progression. Each cycle of treatment lasts 28 days. Cycle 1 to 13 : treatment phase After cycle 13 : maintenance phase

Phase:

Phase 2

Details

Lead Sponsor:

Poitiers University Hospital

Collaborators:

Amgen
Celgene
Intergroupe Francophone du Myelome
Sanofi

Treatments:

Antibodies, Monoclonal
Dexamethasone
Pomalidomide
Thalidomide